

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02607)

CSRC'S APPROVAL ON ISSUANCE OF NEW H SHARES

On 20 September 2019, Shanghai Pharmaceuticals Holding Co., Ltd. (the "**Company**") has received the *Reply on Approving Shanghai Pharmaceuticals Holding Co., Ltd. to Issue Overseas Listed Foreign Shares* from China Securities Regulatory Commission (the "**CSRC**") (Zheng Jian Xu Ke [2019] No. 1676) to approve the Company's issuance of not more than 183,814,540 overseas listed foreign shares, all being ordinary shares with nominal value of RMB 1.00 each.

The issuance still has some uncertainties. If there are any further developments in relation to the issuance, the Company will, in a timely manner, discharge its information disclosure obligation. Investors are advised to be aware of the investment risks involved.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.
ZHOU Jun
Chairman

Shanghai, the PRC, 21 September 2019

As of the date of this announcement, the executive Directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the Independent Non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

** For identification purpose only*